Fluoroquinolone Preventive Therapy Deemed Beneficial in TB

Share this content:
Fluoroquinolone Preventive Therapy Deemed Beneficial in TB
Fluoroquinolone Preventive Therapy Deemed Beneficial in TB

WEDNESDAY, June 17, 2015 (HealthDay News) -- Fluoroquinolone therapy for contacts of individuals with multi-drug resistant tuberculosis is associated with cost savings and reduced incidence of multi-drug resistant tuberculosis, according to a study published online April 27 in the American Journal of Respiratory and Critical Care Medicine.

Gregory J. Fox, M.D., Ph.D., from the Montreal Chest Institute at McGill University, and colleagues examined the potential benefits, risks, and cost-effectiveness of fluoroquinolone therapy to prevent tuberculosis in contacts of individuals with multi-drug resistant tuberculosis. Using decision analysis, costs and outcomes were estimated for no therapy versus a six-month course of daily fluoroquinolone therapy.

The researchers found that, compared with no therapy, fluoroquinolone therapy was associated with health system savings, reduced incidence of multi-drug resistant tuberculosis, and lower mortality. Fluoroquinolone therapy of infected contacts would also result in reduced incidence of multi-drug resistant tuberculosis with acquired fluoroquinolone resistance.

"In our model, fluoroquinolone preventive therapy resulted in substantial health system savings and in reduced mortality, incidence of multi-drug resistant tuberculosis, and incidence of acquired fluoroquinolone resistant disease as well as improved quality of life," the authors write. "Fluoroquinolone therapy remained cost saving with improved outcomes even if the effectiveness of therapy in preventing multi-drug resistant tuberculosis was as low as 10 percent."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »